Biological phenotype of HIV type 2 isolates correlates with V3 genotype

AIDS Research and Human Retroviruses

Volumn 12, Issue 9, 1996, Pages 821-828

  Albert, Jan ^a   Stålhandske, Per ^b   Marquina, Silvia ^a   Karis, Jenny ^b   Fouchier, Ron A M ^c   Norrby, Erling ^b   Chiodi, Francesca ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MONONUCLEAR CELL; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0029892827     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.821     Document Type: Article

References (51)

1. Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey M-A, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, Klatzmann D, Champalimaud JL, and Montagnier L: Isolation of a new human retrovirus from West African patients with AIDS. Science 1986;233:343-346.
2. Albert J, Bredberg U, Chiodi F, Böttiger B, Fenyö EM, Norrby E, and Biberfeld G: A new human retrovirus isolate of West African origin and its relationship to HTLV-IV, LAV-II and HTLV-IIIB. AIDS Res Hum Retroviruses 1987;3:3-10.
3. De Cock KM and Brun-Vezinet F: Epidemiology of HIV-2 infection. AIDS 1989;3(Suppl. 1):S89-S95.
4. Kawamura M, Yamazaki S, Ishikawa K, Kwofie TB, Tsujimoto H, and Hayami M: HIV-2 in west Africa in 1966. Lancet 1989;1:385.
5. CDC: Update: HIV-2 infection - United States. MMWR 1989; 38:572-580.
6. Veronesi R, Mazza CC, Santos Ferreira MO, and Lourenco MH: HIV-2 in Brazil. Lancet 1987;2:402.
7. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, and Alizon M: Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (London) 1987;326:662-669.
8. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, Helliger J, Guèye-Ndiaye A, Sankalé J-L, Ndoye I, Mboup S, and Essex M: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1590.
9. Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, Hart CE, Hessol NA, and Holmberg SD: Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: Immunologic and virologic characteristics. J Infect Dis 1991;163:959-965.
10. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O'Malley PM, Buchbinder SP, Barnhart JL, Bodecker TW, Cannon L, Doll LS, Holmberg SD, Harrison JS, Rodgers MF, Werdegar D, and Jaffe HW: Course of HIV-I infection in a cohort of homosexual and bisexual men: An 11 year follow up study. Br Med J 1990;301:1183-1188.
11. Björling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, and Fenyö EM: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193:528-530.
12. Palker TJ, Clark ME, Langois A, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, and Haynes BF: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-1936.
13. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Matthews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
14. Björling E, Broliden K, Bernardi D, Utter G, Thorstensson R, Chiodi F, and Norrby E: Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci USA 1991;88:6082-6086.
15. Björling E, Chiodi F, Utter G, and Norrby E: Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 1994;152:1952-1959.
16. Åsjö B, Morfeldt-Månsson L, Albert J, Biberfeld G, Karlsson A, Lidman K, and Fenyö EM: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;ii:660-662.
17. Fenyö EM, Morfeldt-Månsson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, and Åsjö B: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
18. Tersmette M, de Goede REY, Al BJM, Winkler IN, Gruters RA, Cuypers HT, Huisman HG, and Miedema F: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
19. De Wolf F, Hogervorst E, Goudsmit J, Fenyö EM, Rübsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SDK, Baan E, Zorgdrager F, Lukasov V, Osmanov S, Kuiken K, Cornelissen M, and the WHO Network for HIV Isolation and Characterization: Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency type 1 subtypes other than B: Phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994;10:1387-1400.
20. Fiore J, Björndal Å, Aperia-Peipke K, Di Stefano M, Angarano G, Pastore, G, Gaines H, Fenyö EM, and Albert J: The biological phenotype of HIV-1 is usually preserved during and after sexual transmission. Virology 1994;204:297-303.
21. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, and Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
22. Karlsson A, Parsmyr K, Sandström E, Fenyö EM, and Albert J: MT-2 cell tropism as a prognostic marker for disease progression in HIV-1 infection. J Clin Microbiol 1994;32:364-370.
23. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
24. Groenink M, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC, Schuitemaker H, de Goede RE, Bosch ML, Huisman HG, and Tersmette M: Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: Evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992;66:6175-6180.
25. Albert J, Nauclér A, Böttiger B, Broliden P-A, Albino P, Oattara AS, Björkegren C, Valentin A, Biberfeld G, and Fenyö EM: Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 1990;4:291-295.
26. Albert J and Fenyö EM: Simple, sensitive and specific detection of HIV-1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 1990;28:1560-1564.
27. Hultman T, Stähl S, Homes E, and Uhlén M: Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res 1989;17:4937-4946.
28. Hultman T, Bergh S, Moks T, and Uhlén M: Bidirectional solid-phase sequencing of in vitro-amplified plasmid DNA. Biotechniques 1991;10:84-93.
29. Wahlberg J, Albert J, Lundeberg J, von Gegerfelt A, Broliden K, Utter G, Fenyö EM, and Uhlén M: Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid phase DNA sequencing. AIDS Res Humn Retroviruses 1991;7:983-989.
30. Myers G, Korber B, Wain-Hobson S, Smith RF, and Pavlakis GN: Human Retroviruses and AIDS 1993. Theoretical Biology and Biophysics, Group T-10, Los Alamos National Laboratory, Los Alamos, New Mexico, 1993.
31. Franchini G, Fargnoli K, Giombini F, Jagodzinsky L, de Rossi A, Bosch M, Biberfeld G, Fenyö EM, Albert J, Gallo R, and Wong-Staal F: Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci USA 1989;86:2433-2437.
32. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninski J, Morfeldt-Månsson L, Åsjö B, and Wain-Hobson S: Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989;58:901-910.
33. Smith S: GDE: Genetic Data Environment, version 2.2. Millipore Imaging Systems, Ann Arbor, Michigan, 1992.
34. Felsenstein J: PHYLIP: Phylogenetic Inference Package, version 3.52c. University of Washington, Seattle, Washington, 1993.
35. Korber B and Myers G: Signature pattern analysis: A method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992;8:1549-1560.
36. Korber BTM, Osmanov S, Esparza J, Myers G, and the WHO Network for HIV Isolation and Characterization: The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. AIDS Res Hum Retroviruses 1994;10:1355-1358.
37. Kong LI, Lee SW, Kappes JC, Parkin JS, Decker D, Hoxie JA, Hahn BH, and Shaw GM: West African HIV-2-related human retrovirus with attenuated cytopathicity. Science 1988;240: 1525-1529.
38. Kumar P, Hui HX, Kappes JC, Haggarty BS, Hoxie JA, Arya SK, Shaw GM, and Hahn BH: Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol 1990;64:890-901.
39. Ishikawa K, Tsujimoto H, Nakai M, Mingle JA, Osei-Kwasi M, Aggrey SE, Nettey VB, Afoakwa SN, Fukasawa M, Kodama T, Kawamura M, and Hyayami M: Isolation and characterization of HIV-2 from an AIDS patient in Ghana. AIDS 1988;2: 383-388.
40. Kirchhoff F, Jentsch KD, Stuke A, Mous J, and Hunsmann G: Genomic divergence of an HIV-2 from a German AIDS patient probably infected in Mali. AIDS 1990;4:847-857.
41. Kühnel H, von Briesen H, Dietrich U, Adamski M, Mix D, Biesert L, Kreutz R, Immelmann A, Henco K, Meichsner C, Andreesen R, and Gelderblom H: Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: A Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci USA 1989; 86:2383-2387.
42. Tristem M, Hill F, and Karpas A: Nucleotide sequence of a Guinea-Bissau-derived human immunodeficiency virus type 2 proviral clone (HIV-2CAM2). J Gen Virol 1991;72:721-724.
43. Zagury JF, Franchini G, Reitz M, Collalti E, Starcich B, Hall L, Fargnoli K, Jagodzinski L, Guo HG, Laure F, Arya SK, Josephs S, Zagury D, Wong-Staal F, and Gallo RC: Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci USA 1988;85:5941-5945.
44. Hillis DM and Bull JJ: An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst Biol 1993;42:182-192.
45. Myers G: Assimilating HIV sequences. AIDS Res Hum Retroviruses 1993;9:697-702.
46. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, and Hahn BH: Human infection by genetically diverse SIVsm-related HIV-2 in West Africa. Nature (London) 1992;358:495-499.
47. Gao F, Ling Y, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM, Sharp PM, and Hahn BH: Genetic diversity of human immunodeficiency virus type 2: Evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994;68:7433-7447.
48. Garnier J, Osguthorpe DJ, and Robson B: Analysis of the accuracy and implication of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978;120:97-120.
49. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nyström G, and Fenyö EM: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
50. von Gegerfelt A, Albert J, Morfeldt-Månsson L, Broliden K, and Fenyö EM: Isolate-specific neutralizing antibodies in patients with progressive HIV-1 related disease. Virology 1991;185:162-168.
51. Boeri E, Giri A, Lillo F, Ferrari G, Varnier OE, Ferro A, Sabbatani S, Saxinger WC, and Franchini G: In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. J Virol 1992;66:4546-4550.